Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | FPR1 | P21462 | 3/20 | 0.32 |
| ▸ | FPR2 | P25090 | 1/20 | 0.32 |
| ▸ | USP7 | Q93009 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4775482 | 0.75 | WDR5 (0.41) | KDM4ETLR8TLR7 | |
| SCHEMBL5345157 | 0.72 | DRD2 (0.47) | KDM4E | |
| SCHEMBL27640735 | 0.72 | DRD2 (0.47) | TLR8TLR7 | |
| SCHEMBL5342788 | 0.71 | DRD2 (0.38) | KDM4ETLR8TLR7SLC6A2SLC6A4 | |
| SCHEMBL4765033 | 0.70 | KDM4E (0.41) | KDM4ENPSR1 | |
| SCHEMBL4769826 | 0.69 | HTR6 (0.36) | KDM4E | |
| SCHEMBL4764984 | 0.67 | NAMPT (0.56) | — | |
| SCHEMBL31702082 | 0.67 | POLB (0.42) | KDM4ETLR8HSD17B10SLC6A2SLC6A4 | |
| SCHEMBL19069574 | 0.67 | SLC6A2 (0.40) | TLR8TLR7SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4791557 | 0.66 | DRD2 (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1590326-A4 | SUBSTITUTED ALKYL AMIDO PIPERIDINES | LUNDBECK & CO AS H (DK) | 2008-04-30 | — | — | EP | disclosed |
| US-7199135-B2 | Substituted alkyl amido piperidines | H. LUNDBECK A/S (DK) | 2007-04-03 | — | — | US | disclosed |
| US-7199135-B2 | Substituted alkyl amido piperidines | H. LUNDBECK A/S (DK) | 2007-04-03 | — | — | US | disclosed |
| US-7199135-B2 | Substituted alkyl amido piperidines | H. LUNDBECK A/S (DK) | 2007-04-03 | — | — | US | disclosed |
| US-20060217418-A1 | Substituted alkyl amido piperidines | H. LUNDBECK A/S (DK) | 2006-09-28 | — | — | US | disclosed |
| US-20060084649-A9 | Substituted alkyl amido piperidines | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2006-04-20 | — | — | US | disclosed |
| EP-1590326-A2 | SUBSTITUTED ALKYL AMIDO PIPERIDINES | H. Lundbeck A/S (DK) | 2005-11-02 | — | — | EP | disclosed |
| US-20040186103-A1 | Substituted alkyl amido piperidines | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-09-23 | — | — | US | disclosed |
| WO-2004064764-A2 | SUBSTITUTED ALKYL AMIDO PIPERIDINES | H. LUNDBECK A/S (DK) | 2004-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084649-A9 | Substituted alkyl amido piperidines | MCHR1, MCHR2, MC1R | KDM4E 1703/4885TLR8 1561/4885TLR7 596/4885 |
| US-20060217418-A1 | Substituted alkyl amido piperidines | MCHR1, MCHR2, MC1R | KDM4E 1703/4885TLR8 1561/4885TLR7 596/4885 |
| US-20040186103-A1 | Substituted alkyl amido piperidines | MCHR1, MCHR2, MC1R | KDM4E 1703/4885TLR8 1561/4885TLR7 596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.